1678-14-4

NSC81111 displayed stronger antiproliferative activities than erlotinib with IC50 values between 0.95 and 17.71 μM against overexpressed EGFR-TK cancer cell lines: A431 and HeLa. Furthermore, calculations of the physicochemical properties suggest the compounds are drug-like and are potentially active orally.

NSC81111 is a potent and orally active EGFR-TK inhibitor with an IC50 of 0.15 nM. NSC81111 has anticaner effects[1].

[1] Nattanan Jiwacharoenchai, et al. Discovery of potent antiproliferative agents from selected oxygen heterocycles as EGFR tyrosine kinase inhibitors from the U.S. National Cancer Institute database by in silico screening and bioactivity evaluation. Bioorg M DOI:10.1016/j.bmcl.2021.128524